Targeting Androgen Receptor Aberrations in Castration-Resistant Prostate Cancer.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 27330057.
- Also identified by DOI 10.1158/1078-0432.CCR-16-1137 and PMC identifier 5302169.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Androgen receptor (AR) splice variants (SV) have been implicated in the development of metastatic castration-resistant prostate cancer and resistance to AR targeting therapies, including abiraterone and enzalutamide. Agents targeting AR-SV are urgently needed to test this hypothesis and further improve the outcome of patients suffering from this lethal disease. Clin Cancer Res; 22(17); 4280-2. ©2016 AACRSee related article by Yang et al., p. 4466.
Medical subject headings
- Androgen Receptor Antagonists
- Antineoplastic Agents
- Molecular Targeted Therapy
- Prostatic Neoplasms, Castration-Resistant
- Receptors, Androgen